Official reprint from UpToDate®
www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Fetal growth restriction: Evaluation and management

Robert Resnik, MD
Section Editors
Charles J Lockwood, MD, MHCM
Deborah Levine, MD
Deputy Editor
Vanessa A Barss, MD, FACOG


When ultrasound examination suggests fetal growth restriction (FGR), prenatal care involves confirming the suspected diagnosis, determining the cause and severity of FGR, counseling the parents, closely monitoring fetal growth and well-being, and determining the optimal time for and route of delivery. FGR resulting from intrinsic fetal factors such as aneuploidy, congenital malformations, or infection carries a guarded prognosis that often cannot be improved by any intervention. FGR related to uteroplacental insufficiency has a better prognosis, but the risk for adverse outcome remains increased.

This topic will discuss the evaluation and management of pregnancies complicated by FGR. The diagnosis of FGR and outcome of affected infants are reviewed separately. (See "Fetal growth restriction: Diagnosis" and "Infants with fetal (intrauterine) growth restriction".)


Confirm the diagnosis

Our approach — The diagnosis of FGR is based on discrepancies between actual and expected sonographic biometric measurements for a given gestational age. Traditionally, it has been defined as <10th percentile weight for gestational age on a singleton growth curve, and this establishes the diagnosis as being small for gestational age (SGA). In our practice, when a fetus <10th percentile weight for gestational age is identified, we monitor fetal growth and fetal physiology over time. A normal growth trajectory, normal Doppler velocimetry of the umbilical artery, and normal amniotic fluid volume suggest a constitutionally small fetus or minimal fetal impact from uteroplacental insufficiency. (See 'Pregnancy management' below.)

A weight <10th percentile definition is clinically practical, but it alone does not distinguish the constitutionally small fetus that achieves its normal growth potential and is not at increased risk of adverse outcome from the similarly small fetus whose growth potential is restricted and is at increased risk of perinatal morbidity and mortality. This definition also does not account for the fetus who is not small, but not achieving its growth potential because of intrinsic or environmental restrictions to normal growth. Distinguishing the constitutionally small fetus from the fetus with pathologic growth restriction is the first challenge for the clinician; it can help to avoid unnecessary interventions for pregnancies with a constitutionally small fetus and appropriately monitor and time delivery, which may be preterm, of the growth restricted fetus.

Characteristics that support a diagnosis of a constitutionally small fetus include modest smallness (ie, estimated weight between the 5th and 10th percentiles), normal growth velocity across gestation, normal physiology (ie, normal amniotic fluid volume and umbilical artery Doppler), abdominal circumference growth velocity above the lowest decile, and appropriate size in terms of maternal characteristics (height, weight, race/ethnicity), which have a major influence on fetal growth potential. For example, when race/ethnicity was taken into account, the 5th percentiles for white, Hispanic, black, and Asian women were 2790, 2633, 2622, and 2621 grams, respectively, in a prospective study of 2334 healthy women with low-risk, singleton pregnancies from 12 medical centers in the United States. Using biometric standards derived solely from the group of white fetuses, as many as 15 percent of the non-white fetuses would have been classified as growth-restricted (<5th percentile) [1].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Dec 2017. | This topic last updated: Jan 05, 2018.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2018 UpToDate, Inc.
  1. Buck Louis GM, Grewal J, Albert PS, et al. Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies. Am J Obstet Gynecol 2015; 213:449.e1.
  2. Unterscheider J, Daly S, Geary MP, et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. Am J Obstet Gynecol 2013; 208:290.e1.
  3. Mlynarczyk M, Chauhan SP, Baydoun HA, et al. The clinical significance of an estimated fetal weight below the 10th percentile: a comparison of outcomes of <5th vs 5th-9th percentile. Am J Obstet Gynecol 2017; 217:198.e1.
  4. Barker ED, McAuliffe FM, Alderdice F, et al. The role of growth trajectories in classifying fetal growth restriction. Obstet Gynecol 2013; 122:248.
  5. Gardosi J. New definition of small for gestational age based on fetal growth potential. Horm Res 2006; 65 Suppl 3:15.
  6. Gardosi J, Figueras F, Clausson B, Francis A. The customised growth potential: an international research tool to study the epidemiology of fetal growth. Paediatr Perinat Epidemiol 2011; 25:2.
  7. Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. Am J Obstet Gynecol 2011; 204:288.
  8. Mendez H. Introduction to the study of pre- and postnatal growth in humans: a review. Am J Med Genet 1985; 20:63.
  9. Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988; 82:83.
  10. Taylor-Phillips S, Freeman K, Geppert J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open 2016; 6:e010002.
  11. Zhu H, Lin S, Huang L, et al. Application of chromosomal microarray analysis in prenatal diagnosis of fetal growth restriction. Prenat Diagn 2016; 36:686.
  12. Sagi-Dain L, Peleg A, Sagi S. Risk for chromosomal aberrations in apparently isolated intrauterine growth restriction: A systematic review. Prenat Diagn 2017; 37:1061.
  13. Grivell RM, Wong L, Bhatia V. Regimens of fetal surveillance for impaired fetal growth. Cochrane Database Syst Rev 2012; :CD007113.
  14. Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 2001; 18:571.
  15. Ferrazzi E, Bozzo M, Rigano S, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol 2002; 19:140.
  16. Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001; 18:564.
  17. Cosmi E, Ambrosini G, D'Antona D, et al. Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses. Obstet Gynecol 2005; 106:1240.
  18. Baschat AA. Venous Doppler evaluation of the growth-restricted fetus. Clin Perinatol 2011; 38:103.
  19. Baschat AA. Ductus venosus Doppler for fetal surveillance in high-risk pregnancies. Clin Obstet Gynecol 2010; 53:858.
  20. Unterscheider J, Daly S, Geary MP, et al. Predictable progressive Doppler deterioration in IUGR: does it really exist? Am J Obstet Gynecol 2013; 209:539.e1.
  21. Turan OM, Turan S, Gungor S, et al. Progression of Doppler abnormalities in intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 32:160.
  22. Baschat AA, Galan HL, Bhide A, et al. Doppler and biophysical assessment in growth restricted fetuses: distribution of test results. Ultrasound Obstet Gynecol 2006; 27:41.
  23. Lausman A, McCarthy FP, Walker M, Kingdom J. Screening, diagnosis, and management of intrauterine growth restriction. J Obstet Gynaecol Can 2012; 34:17.
  24. Gülmezoglu AM, Hofmeyr GJ. Bed rest in hospital for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000034.
  25. Zelop CM, Javitt MC, Glanc P, Dubinsky T, Harisinghani MG, Harris RD, Khati NJ, Mitchell DG, Pandharipande PV, Pannu HK, Podrasky AE, Shipp TD, Siegel CL, Simpson L, Wall DJ, Wong-You-Cheong JJ, Expert Panel on Women's Imaging. ACR Appropriateness Criteria® growth disturbances -- risk of intrauterine growth restriction. [online publication]. Reston (VA): American College of Radiology (ACR); 2012. 7 p. [24 references] http://www.guideline.gov/content.aspx?f=rss&id=43884&osrc=12 (Accessed on August 28, 2013).
  26. Dayal AK, Manning FA, Berck DJ, et al. Fetal death after normal biophysical profile score: An eighteen-year experience. Am J Obstet Gynecol 1999; 181:1231.
  27. Scifres CM, Stamilio D, Macones GA, Odibo AO. Predicting perinatal mortality in preterm intrauterine growth restriction. Am J Perinatol 2009; 26:723.
  28. Chauhan SP, Taylor M, Shields D, et al. Intrauterine growth restriction and oligohydramnios among high-risk patients. Am J Perinatol 2007; 24:215.
  29. Society for Maternal-Fetal Medicine Publications Committee, Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Am J Obstet Gynecol 2012; 206:300.
  30. Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2013; :CD007529.
  31. O'Dwyer V, Burke G, Unterscheider J, et al. Defining the residual risk of adverse perinatal outcome in growth-restricted fetuses with normal umbilical artery blood flow. Am J Obstet Gynecol 2014; 211:420.e1.
  32. Baschat AA. Fetal growth restriction - from observation to intervention. J Perinat Med 2010; 38:239.
  33. Maggio L, Dahlke JD, Mendez-Figueroa H, et al. Perinatal outcomes with normal compared with elevated umbilical artery systolic-to-diastolic ratios in fetal growth restriction. Obstet Gynecol 2015; 125:863.
  34. Vasconcelos RP, Brazil Frota Aragão JR, Costa Carvalho FH, et al. Differences in neonatal outcome in fetuses with absent versus reverse end-diastolic flow in umbilical artery Doppler. Fetal Diagn Ther 2010; 28:160.
  35. Baschat AA, Gembruch U, Weiner CP, Harman CR. Qualitative venous Doppler waveform analysis improves prediction of critical perinatal outcomes in premature growth-restricted fetuses. Ultrasound Obstet Gynecol 2003; 22:240.
  36. Turan OM, Turan S, Berg C, et al. Duration of persistent abnormal ductus venosus flow and its impact on perinatal outcome in fetal growth restriction. Ultrasound Obstet Gynecol 2011; 38:295.
  37. Baschat AA. Doppler application in the delivery timing of the preterm growth-restricted fetus: another step in the right direction. Ultrasound Obstet Gynecol 2004; 23:111.
  38. Bilardo CM, Wolf H, Stigter RH, et al. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gynecol 2004; 23:119.
  39. Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet 2015; 385:2162.
  40. Bahado-Singh RO, Kovanci E, Jeffres A, et al. The Doppler cerebroplacental ratio and perinatal outcome in intrauterine growth restriction. Am J Obstet Gynecol 1999; 180:750.
  41. Mari G, Deter RL. Middle cerebral artery flow velocity waveforms in normal and small-for-gestational-age fetuses. Am J Obstet Gynecol 1992; 166:1262.
  42. Schenone MH, Mari G. The MCA Doppler and its role in the evaluation of fetal anemia and fetal growth restriction. Clin Perinatol 2011; 38:83.
  43. Simpson L, Khati NJ, Deshmukh SP, et al. ACR Appropriateness Criteria Assessment of Fetal Well-Being. J Am Coll Radiol 2016; 13:1483.
  44. Morales-Roselló J, Khalil A. Fetal cerebral redistribution: a marker of compromise regardless of fetal size. Ultrasound Obstet Gynecol 2015; 46:385.
  45. Flood K, Unterscheider J, Daly S, et al. The role of brain sparing in the prediction of adverse outcomes in intrauterine growth restriction: results of the multicenter PORTO Study. Am J Obstet Gynecol 2014; 211:288.e1.
  46. Regan J, Masters H, Warshak CR. Estimation of the growth rate in fetuses with an abnormal cerebroplacental ratio compared to those with suspected growth restriction without evidence of centralization of blood flow. J Ultrasound Med 2015; 34:837.
  47. Khalil AA, Morales-Rosello J, Elsaddig M, et al. The association between fetal Doppler and admission to neonatal unit at term. Am J Obstet Gynecol 2015; 213:57.e1.
  48. Khalil AA, Morales-Rosello J, Morlando M, et al. Is fetal cerebroplacental ratio an independent predictor of intrapartum fetal compromise and neonatal unit admission? Am J Obstet Gynecol 2015; 213:54.e1.
  49. Elimian A, Verma U, Canterino J, et al. Effectiveness of antenatal steroids in obstetric subgroups. Obstet Gynecol 1999; 93:174.
  50. Schaap AH, Wolf H, Bruinse HW, et al. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol 2001; 97:954.
  51. Gardosi JO. Prematurity and fetal growth restriction. Early Hum Dev 2005; 81:43.
  52. Bukowski R, Gahn D, Denning J, Saade G. Impairment of growth in fetuses destined to deliver preterm. Am J Obstet Gynecol 2001; 185:463.
  53. Doubilet PM, Benson CB, Wilkins-Haug L, Ringer S. Fetuses subsequently born premature are smaller than gestational age-matched fetuses not born premature. J Ultrasound Med 2003; 22:359.
  54. Robertson MC, Murila F, Tong S, et al. Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus. Obstet Gynecol 2009; 113:636.
  55. Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190:296.
  56. Nozaki AM, Francisco RP, Fonseca ES, et al. Fetal hemodynamic changes following maternal betamethasone administration in pregnancies with fetal growth restriction and absent end-diastolic flow in the umbilical artery. Acta Obstet Gynecol Scand 2009; 88:350.
  57. Gülmezoglu AM, Hofmeyr GJ. Plasma volume expansion for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000167.
  58. Gülmezoglu AM, Hofmeyr GJ. Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000148.
  59. Newnham JP, Godfrey M, Walters BJ, et al. Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. Aust N Z J Obstet Gynaecol 1995; 35:370.
  60. Gülmezoglu AM, Hofmeyr GJ. Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000137.
  61. Yu YH, Shen LY, Zou H, et al. Heparin for patients with growth restricted fetus: a prospective randomized controlled trial. J Matern Fetal Neonatal Med 2010; 23:980.
  62. von Dadelszen P, Dwinnell S, Magee LA, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011; 118:624.
  63. Wyrwoll CS, Noble J, Thomson A, et al. Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess. Proc Natl Acad Sci U S A 2016; 113:6265.
  64. Kubo M, Umekawa T, Maekawa Y, et al. Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes. J Obstet Gynaecol Res 2017; 43:291.
  65. Ganzevoort W, Alfirevic Z, von Dadelszen P, et al. STRIDER: Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction--a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev 2014; 3:23.
  66. Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest 2016; 126:2933.
  67. Kubo M, Tanaka H, Maki S, et al. Safety and dose-finding trial of tadalafil administered for fetal growth restriction: A phase-1 clinical study. J Obstet Gynaecol Res 43:1159.
  68. Paauw ND, Terstappen F, Ganzevoort W, et al. Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure. Hypertension 2017; 70:998.
  69. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014; :CD002252.
  70. Figueras F, Meler E, Eixarch E, et al. Association of smoking during pregnancy and fetal growth restriction: subgroups of higher susceptibility. Eur J Obstet Gynecol Reprod Biol 2008; 138:171.
  71. Aagaard-Tillery KM, Porter TF, Lane RH, et al. In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth. Am J Obstet Gynecol 2008; 198:66.e1.
  72. When do obstetricians recommend delivery for a high-risk preterm growth-retarded fetus? The GRIT Study Group. Growth Restriction Intervention Trial. Eur J Obstet Gynecol Reprod Biol 1996; 67:121.
  73. Thornton JG, Hornbuckle J, Vail A, et al. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. Lancet 2004; 364:513.
  74. Walker DM, Marlow N, Upstone L, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol 2011; 204:34.e1.
  75. Boers KE, Vijgen SM, Bijlenga D, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). BMJ 2010; 341:c7087.
  76. Boers KE, van Wyk L, van der Post JA, et al. Neonatal morbidity after induction vs expectant monitoring in intrauterine growth restriction at term: a subanalysis of the DIGITAT RCT. Am J Obstet Gynecol 2012; 206:344.e1.
  77. van Wyk L, Boers KE, van der Post JA, et al. Effects on (neuro)developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial. Am J Obstet Gynecol 2012; 206:406.e1.
  78. Visser GHA, Bilardo CM, Derks JB, et al. Fetal monitoring indications for delivery and 2-year outcome in 310 infants with fetal growth restriction delivered before 32 weeks' gestation in the TRUFFLE study. Ultrasound Obstet Gynecol 2017; 50:347.
  79. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196:147.e1.
  80. Lees C, Marlow N, Arabin B, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol 2013; 42:400.
  81. Baschat AA, Cosmi E, Bilardo CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol 2007; 109:253.
  82. Pilliod RA, Cheng YW, Snowden JM, et al. The risk of intrauterine fetal death in the small-for-gestational-age fetus. Am J Obstet Gynecol 2012; 207:318.e1.
  83. Bernardes TP, Broekhuijsen K, Koopmans CM, et al. Caesarean section rates and adverse neonatal outcomes after induction of labour versus expectant management in women with an unripe cervix: a secondary analysis of the HYPITAT and DIGITAT trials. BJOG 2016; 123:1501.
  84. Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99:490.
  85. Baschat AA, Weiner CP. Umbilical artery doppler screening for detection of the small fetus in need of antepartum surveillance. Am J Obstet Gynecol 2000; 182:154.
  86. American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol 2013; 121:1122.
  87. Werner EF, Savitz DA, Janevic TM, et al. Mode of delivery and neonatal outcomes in preterm, small-for-gestational-age newborns. Obstet Gynecol 2012; 120:560.
  88. Chauhan SP, Rice MM, Grobman WA, et al. Neonatal Morbidity of Small- and Large-for-Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies. Obstet Gynecol 2017; 130:511.
  89. Temming LA, Dicke JM, Stout MJ, et al. Early Second-Trimester Fetal Growth Restriction and Adverse Perinatal Outcomes. Obstet Gynecol 2017; 130:865.
  90. Monier I, Ancel PY, Ego A, et al. Gestational age at diagnosis of early-onset fetal growth restriction and impact on management and survival: a population-based cohort study. BJOG 2017; 124:1899.
  91. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001; 357:2002.
  92. Patterson RM, Gibbs CE, Wood RC. Birth weight percentile and perinatal outcome: recurrence of intrauterine growth retardation. Obstet Gynecol 1986; 68:464.
  93. Voskamp BJ, Kazemier BM, Ravelli AC, et al. Recurrence of small-for-gestational-age pregnancy: analysis of first and subsequent singleton pregnancies in The Netherlands. Am J Obstet Gynecol 2013; 208:374.e1.
  94. Bakketeig LS, Bjerkedal T, Hoffman HJ. Small-for-gestational age births in successive pregnancy outcomes: results from a longitudinal study of births in Norway. Early Hum Dev 1986; 14:187.
  95. Ananth CV, Kaminsky L, Getahun D, et al. Recurrence of fetal growth restriction in singleton and twin gestations. J Matern Fetal Neonatal Med 2009; 22:654.
  96. Surkan PJ, Stephansson O, Dickman PW, Cnattingius S. Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth. N Engl J Med 2004; 350:777.
  97. Salihu HM, Sharma PP, Aliyu MH, et al. Is small for gestational age a marker of future fetal survival in utero? Obstet Gynecol 2006; 107:851.
  98. Gordon A, Raynes-Greenow C, McGeechan K, et al. Stillbirth risk in a second pregnancy. Obstet Gynecol 2012; 119:509.
  99. Smith GC, Wood AM, Pell JP, Dobbie R. Sudden infant death syndrome and complications in other pregnancies. Lancet 2005; 366:2107.
  100. Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216:110.
  101. Rodger MA, Gris JC, de Vries JP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016.
  102. Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol 2017; 216:296.e1.
  103. Horvath A, Koletzko B, Szajewska H. Effect of supplementation of women in high-risk pregnancies with long-chain polyunsaturated fatty acids on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials. Br J Nutr 2007; 98:253.
  104. Gülmezoglu AM, Hofmeyr GJ. Betamimetics for suspected impaired fetal growth. Cochrane Database Syst Rev 2001; :CD000036.
  105. Morris RK, Malin G, Robson SC, et al. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 37:135.
  106. Vayssière C, Sentilhes L, Ego A, et al. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. Eur J Obstet Gynecol Reprod Biol 2015; 193:10.